|
1.
|
|
12 p, 2.4 MB |
Interim Results from the IMPACT Study : Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
/
Page, Elizabeth C. (Institute of Cancer Research) ;
Bancroft, Elizabeth K. (Royal Marsden NHS Foundation Trust) ;
Brook, Mark N. (Institute of Cancer Research) ;
Assel, Melissa (Memorial Sloan Kettering Cancer Center) ;
Hassan Al Battat, Mona (Lund University) ;
Thomas, Sarah (Royal Marsden NHS Foundation Trust) ;
Taylor, Natalie (Royal Marsden NHS Foundation Trust) ;
Chamberlain, Anthony (Institute of Cancer Research) ;
Pope, Jennifer (Institute of Cancer Research) ;
Raghallaigh, Holly Ni (Institute of Cancer Research) ;
Evans, D.Gareth (Central Manchester University Hospitals NHS Foundation Trust) ;
Rothwell, Jeanette (Central Manchester University Hospitals NHS Foundation Trust) ;
Maehle, Lovise (Oslo University Hospital (Oslo, Noruega)) ;
Grindedal, Eli Marie (Oslo University Hospital (Oslo, Noruega)) ;
James, Paul (The Royal Melbourne Hospital) ;
Mascarenhas, Lyon (Peter MacCallum Cancer Centre) ;
McKinley, Joanne (Peter MacCallum Cancer Centre) ;
Side, Lucy (Princess Anne Hospital) ;
Thomas, Tessy (Princess Anne Hospital) ;
van Asperen, Christi (Leiden University Medical Center) ;
Vasen, Hans (The Foundation for the Detection of Hereditary Cancer) ;
Kiemeney, Lambertus A. (Radboud University Medical Center) ;
Ringelberg, Janneke (The Foundation for the Detection of Hereditary Cancer) ;
Jensen, Thomas Dyrso. (Vejle Hospital) ;
Osther, Palle J.S. (Vejle Hospital) ;
Helfand, Brian T. (NorthShore University HealthSystem) ;
Genova, Elena (NorthShore University HealthSystem) ;
Oldenburg, Rogier A. (Erasmus University Medical Center) ;
Cybulski, Cezary (Pomeranian Medical University in Szczecin) ;
Wokolorczyk, Dominika (Pomeranian Medical University in Szczecin) ;
Ong, Kai-Ren (Birmingham Women's Hospital) ;
Huber, Camilla (Birmingham Women's Hospital) ;
Lam, Jimmy (Bedford Park) ;
Taylor, Louise (Daw Park) ;
Salinas, Monica (Hospital Universitari de Bellvitge) ;
Feliubadaló, Lidia (Hospital Universitari de Bellvitge) ;
Oosterwijk, Jan C. (University of Groningen) ;
van Zelst-Stams, Wendy (Radboud University Medical Center) ;
Cook, Jackie (Sheffield Children's Hospital (Sheffield, Regne Unit)) ;
Rosario, Derek J. (Royal Hallamshire Hospital) ;
Domchek, Susan (Basser Research Center. University of Pennsylvania) ;
Powers, Jacquelyn (University of Pennsylvania) ;
Buys, Saundra (University of Utah) ;
O'Toole, Karen (University of Utah) ;
Ausems, Margreet G. E. M (University Medical Centre) ;
Schmutzler, Rita K. (University Hospital Cologne) ;
Rhiem, Kerstin (University Hospital Cologne) ;
Izatt, Louise (Guy's and St Thomas' NHS Foundation Trust) ;
Tripathi, Vishakha (Guy's and St Thomas' NHS Foundation Trust) ;
Teixeira, Manuel R. (Porto University) ;
Cardoso, Marta (Portuguese Oncology Institute (IPO Porto)) ;
Foulkes, William D. (McGill University, Departments of Human Genetics and Oncology) ;
Aprikian, Armen (Research Institute of McGill University Health Centre) ;
van Randeraad, Heleen (The Foundation for the Detection of Hereditary Cancer) ;
Davidson, Rosemarie (Queen Elizabeth University Hospital) ;
Longmuir, Mark (Queen Elizabeth University Hospital) ;
Ruijs, Marielle W.G. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Helderman van den Enden, Apollonia T.J.M. (Maastricht University Medical Center) ;
Adank, Muriel (Amsterdam UMC) ;
Williams, Rachel (Prince of Wales Hospital (Australia)) ;
Andrews, Lesley (Prince of Wales Hospital (Australia)) ;
Murphy, Declan G. (Peter MacCallum Cancer Centre) ;
Halliday, Dorothy (Oxford Centre for Genomic Medicine) ;
Walker, Lisa (Oxford Centre for Genomic Medicine) ;
Liljegren, Annelie (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Carlsson, Stefan (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Azzabi, Ashraf (Newcastle upon Tyne Hospitals) ;
Jobson, Irene (Newcastle upon Tyne Hospitals) ;
Morton, Catherine (The Royal Melbourne Hospital) ;
Shackleton, Kylie (The Royal Melbourne Hospital) ;
Snape, Katie (St George's Hospital) ;
Hanson, Helen (St George's Hospital) ;
Harris, Marion (Monash Health) ;
Tischkowitz, Marc (University of Cambridge) ;
Taylor, Amy (Cambridge University Hospitals NHS Trust) ;
Kirk, Judy (Sydney Medical School) ;
Susman, Rachel (Royal Brisbane & Women's Hospital) ;
Chen-Shtoyerman, Rakefet (Kaplan Medical Center) ;
Spigelman, Allan (The Kinghorn Cancer Centre. St Vincent's Hospital) ;
Pachter, Nicholas (University of Western Australia) ;
Ahmed, Munaza (NE Thames Regional Genetics Service) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
Zgajnar, Janez (Institute of Oncology) ;
Brewer, Carole (Royal Devon and Exeter Hospital) ;
Gadea, Neus (Hospital Universitari Vall d'Hebron) ;
Brady, Angela F. (London North West University Healthcare NHS Trust) ;
van Os, Theo (Academic Medical Center) ;
Gallagher, David (St James's Hospital) ;
Johannsson, Oskar (Landspitali University Hospital (Reykjavík, Islàndia)) ;
Donaldson, Alan (St Michael's Hospital) ;
Barwell, Julian (University Hospitals Leicester) ;
Nicolai, Nicola (Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Friedman, Eitan (Chaim Shema Medical Center) ;
Obeid, Elias (Fox Chase Cancer Center) ;
Greenhalgh, Lynn (Liverpool Women's Hospital) ;
Murthy, Vedana (Tata Memorial Centre) ;
Copakova, Lucia (National Cancer Institute) ;
Saya, Sibel (Institute of Cancer Research) ;
McGrath, John (University of Exeter Medical School) ;
Cooke, Peter (New Cross Hospital) ;
Rønlund, Karina (Vejle Hospital) ;
Richardson, Kate (Peter MacCallum Cancer Centre) ;
Henderson, Alex (West Cumberland Infirmary) ;
Teo, Soo H. (Subang Jaya Medical Centre) ;
Arun, Banu (The University of Texas) ;
Kast, Karin (Technische Universität Dresden) ;
Dias, Alexander (Instituto Nacional de Cancer Jose de Alencar Gomes da Silva (INCA)) ;
Aaronson, Neil K (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Ardern-Jones, Audrey (Royal Marsden NHS Foundation Trust) ;
Bangma, Chris H. (Erasmus University Medical Center) ;
Castro, Elena (Centro Nacional de Investigaciones Oncológicas) ;
Dearnaley, David (The Institute of Cancer Research. Royal Marsden NHS Foundation Trust (Londres, Regne Unit)) ;
Eccles, Diana M. (The University of Southampton Medical School) ;
Tricker, Karen (Central Manchester University Hospitals NHS Foundation Trust) ;
Eyfjord, Jorunn (University of Iceland) ;
Falconer, Alison (Imperial College Healthcare NHS Trust) ;
Foster, Christopher (HCA Pathology Laboratories) ;
Gronberg, Henrik (University Hospital) ;
Hamdy, Freddie C. (University of Oxford) ;
Stefansdottir, Vigdis (Landspitali University Hospital (Reykjavík, Islàndia)) ;
Khoo, Vincent (The University of Melbourne) ;
Lindeman, Geoffrey J. (The Walter and Eliza Hall Institute of Medical Research) ;
Lubinski, Jan (Pomeranian Medical University in Szczecin) ;
Axcrona, Karol (Akershus University Hospital) ;
Mikropoulos, Christos (Medway Hospital) ;
Mitra, Anita (University College London Hospitals NHS Foundation Trust) ;
Moynihan, Clare (Institute of Cancer Research) ;
Rennert, Gadi (Carmel Medical Center) ;
Suri, Mohnish (Nottingham City Hospital) ;
Wilson, Penny (Innovate UK. Polaris House) ;
Dudderidge, Tim (University Hospital Southampton) ;
Offman, Judith (King's College London) ;
Kote-Jarai, Zsofia (Institute of Cancer Research) ;
Vickers, Andrew (Memorial Sloan Kettering Cancer Center) ;
Lilja, Hans (Memorial Sloan-Kettering Cancer Center (Nova York, Estats Units d'Amèrica)) ;
Eeles, Rosalind A. (Royal Marsden NHS Foundation Trust) ;
Universitat Autònoma de Barcelona
Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. [...]
2019 -  10.1016/j.eururo.2019.08.019
European Urology, Vol. 76 Núm. 6 (december 2019) , p. 831-842
|
|
|
2.
|
|
14 p, 1007.9 KB |
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT) : initial results from an international prospective study
/
Bancroft, Elizabeth K. (Royal Marsden NHS Foundation Trust, London) ;
Page, Elizabeth C. (Institute of Cancer Research, London) ;
Brook, Mark N. (Institute of Cancer Research, London) ;
Thomas, Sarah (Royal Marsden NHS Foundation Trust, London) ;
Taylor, Natalie (Royal Marsden NHS Foundation Trust, London) ;
Pope, Jennifer (Institute of Cancer Research, London) ;
McHugh, Jana (Institute of Cancer Research, London) ;
Jones, Ann-Britt (Institute of Cancer Research, London) ;
Karlsson, Questa (Institute of Cancer Research, London) ;
Merson, Susan (Institute of Cancer Research, London) ;
Ong, Kai Ren (Birmingham Women's Hospital) ;
Hoffman, Jonathan (Birmingham Women's Hospital) ;
Huber, Camilla (Birmingham Women's Hospital) ;
Maehle, Lovise (Oslo University Hospital (Oslo, Noruega)) ;
Grindedal, Eli Marie (Oslo University Hospital (Oslo, Noruega)) ;
Stormorken, Astrid (Oslo University Hospital (Oslo, Noruega)) ;
Evans, Gareth (University of Mancheste) ;
Rothwell, Jeanette (University of Manchester) ;
Lalloo, Fiona (University of Manchester) ;
Brady, Angela F. (London North West University Healthcare NHS Trust, Harrow) ;
Bartlett, Marion (London North West University Healthcare NHS Trust, Harrow) ;
Snape, Katie (St George's Hospital, Tooting, London) ;
Hanson, Helen (St George's Hospital, Tooting, London) ;
James, Paul (The University of Melbourne) ;
McKinley, Joanne (Parkville Familial Cancer Centre, Melbourne) ;
Mascarenhas, Lyon (Parkville Familial Cancer Centre, Melbourne) ;
Syngal, Sapna (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Ukaegbu, Chinedu (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Side, Lucy (Wessex Princess Anne Hospital, Southampton) ;
Thomas, Tessy (Princess Anne Hospital, Southampton) ;
Barwell, Julian (University Hospitals Leicester, Leicester) ;
Teixeira, Manuel R. (Porto University, Porto) ;
Izatt, Louise (Guy's and St Thomas' NHS Foundation Trust, London) ;
Suri, Mohnish (Nottingham University Hospitals NHS Trust (Regne Unit)) ;
Macrae, Finlay A. (Royal Melbourne Hospital (Melbourne, Austràlia)) ;
Poplawski, Nicola (University of Adelaide, Adelaide) ;
Chen-Shtoyerman, Rakefet (Ariel University, Ariel) ;
Ahmed, Munaza (Institute of Child Health, London) ;
Musgrave, Hannah (Leeds Teaching Hospitals NHS Trust, Leeds) ;
Nicolai, Nicola (Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Greenhalgh, Lynn (Clinical Genetics Service, Liverpool Women's Hospital, Liverpool) ;
Brewer, Carole (Royal Devon & Exeter Hospital (Exeter, Regne Unit)) ;
Pachter, Nicholas (University of Western Australia, Perth) ;
Spigelman, Allan D. (St Vincent's Hospital (Sydney)) ;
Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne) ;
Helfand, Brian T. (NorthShore University HealthSystem, Evanston) ;
Halliday, Dorothy (Oxford University Hospitals NHS Trust) ;
Buys, Saundra (University of Utah, Salt Lake City) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
Donaldson, Alan (St Michael's Hospital, Bristol) ;
Cooney, Kathleen A. (Duke Cancer Institute and Duke University School of Medicine, Durham) ;
Harris, Marion (Monash University, Clayton) ;
McGrath, John (University of Exeter Medical School, Exeter) ;
Davidson, Rosemarie (Queen Elizabeth University Hospital, Glasgow) ;
Taylor, Amy (Cambridge University Hospitals NHS Foundation Trust (Regne Unit)) ;
Cooke, Peter (New Cross Hospital, Wolverhampton, UK) ;
Myhill, Kathryn (Royal Marsden NHS Foundation Trust, London) ;
Hogben, Matthew (Royal Marsden NHS Foundation Trust, London) ;
Aaronson, Neil K. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Ardern-Jones, Audrey (Royal Marsden NHS Foundation Trust, London) ;
Bangma, Chris H. (Erasmus Cancer Institute, Rotterdam) ;
Castro, Elena (Centro Nacional de Investigaciones Oncológicas) ;
Dearnaley, David (The Institute of Cancer Research, Sutton) ;
Dias, Alexander (Instituto Nacional de Cancer Jose de Alencar Gomes da Silva INCA, Rio de Janeiro) ;
Dudderidge, Tim (University Hospital Southampton) ;
Eccles, Diana M. (University of Southampton, Southampton) ;
Green, Kate (University of Manchester, Manchester) ;
Eyfjord, Jorunn (University of Iceland, Reykjavik) ;
Falconer, Alison (Imperial College Healthcare NHS Trust, London) ;
Foster, Christopher S. (HCA Pathology Laboratories, London) ;
Gronberg, Henrik (University Hospital of Umeå) ;
Hamdy, Freddie C. (University of Oxford) ;
Johannsson, Oskar (Landspitali University Hospital (Reykjavík, Islàndia)) ;
Khoo, Vincent (The Institute of Cancer Research, Sutton, Surrey) ;
Lilja, Hans (Department of Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York) ;
Lindeman, Geoffrey J. (The Walter and Eliza Hall Institute of Medical Research, Parkville) ;
Lubinski, Jan (Pomeranian Medical University in Szczecin) ;
Axcrona, Karol (Department of Urology, Akershus University Hospital, Lørenskog) ;
Mikropoulos, Christos (Royal Surrey County Hospital, Guildford) ;
Mitra, Anita V (University College London Hospitals NHS Foundation Trust, London) ;
Moynihan, Clare (Institute of Cancer Research, London) ;
Ni Raghallaigh, Holly (Institute of Cancer Research, London) ;
Rennert, Gad (CHS National Cancer Control Center, Haifa) ;
Collier, Rebecca (Nottingham University Hospitals NHS Trust (Regne Unit)) ;
Offman, Judith (King's College London) ;
Kote-Jarai, Zsofia (Institute of Cancer Research) ;
Eeles, Rosalind A. (Royal Marsden NHS Foundation Trust, London) ;
Universitat Autònoma de Barcelona
Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer. [...]
2021 - 10.1016/S1470-2045(21)00522-2
The Lancet. Oncology, Vol. 22 (november 2021) , p. 1618-1631
|
|
|
3.
|
|
17 p, 1.9 MB |
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial
/
Iveson, Timothy J. (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Kerr, Rachel S. (Department of Oncology, University of Oxford, Oxford, UK) ;
Saunders, Mark P. (The Christie Hospital, Manchester, UK) ;
Cassidy, Jim (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Hollander, Niels Henrik (Westmead Hospital) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Haydon, Andrew (Australasian Gastro-Intestinal Trials Group, Melbourne, VIC, Australia) ;
Glimelius, Bengt (IGP, University of Uppsala, Uppsala, Sweden) ;
Harkin, Andrea (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Allan, Karen (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
McQueen, John (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Scudder, Claire (OCTO, University of Oxford, Department of Oncology, Oxford, UK) ;
Boyd, Kathleen A. (University of Glasgow. Institute of Health and Wellbeing) ;
Briggs, Andrew (Memorial Sloan-Kettering Cancer Centre) ;
Waterston, Ashita (Beatson West of Scotland Cancer Centre (Glasgow, Regne Unit)) ;
Medley, Louise (Royal United Hospital, Bath, UK) ;
Wilson, Charles (Addenbrookes Hospital (Cambridge, Regne Unit)) ;
Ellis, Richard (Royal Cornwall Hospital NHS Trust, Truro, UK) ;
Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK) ;
Dhadda, Amandeep S. (Castle Hill Hospital) ;
Harrison, Mark (Mount Vernon Cancer Centre, Northwood, UK) ;
Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ;
Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ;
Rees, Charlotte (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Olesen, Rene K. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Propper, David (Barts Cancer Institute (BCI)) ;
Bridgewater, John (UCL Cancer Institute, University College London, London UK) ;
Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK) ;
Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, UK) ;
Webb, Andrew (Brighton and Sussex University Hospital Trust) ;
Cunningham, David (Royal Marsden Hospital (Regne Unit)) ;
Hickish, Tamas (Poole Hospital, Bournemouth University, Bournemouth, UK) ;
Weaver, Andrew (Department of Oncology, Oxford University Hospitals Foundation Trust, Oxford, UK) ;
Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ;
Wasan, Harpreet S.. (Hammersmith Hospital (Londres)) ;
Paul, James (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Universitat Autònoma de Barcelona
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. [...]
2018 - 10.1016/S1470-2045(18)30093-7
The Lancet. Oncology, Vol. 19 (april 2018) , p. 562-578
|
|
|
4.
|
|
7 p, 434.6 KB |
SCOT : a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
/
Robles-Zurita, José (University of Glasgow. Institute of Health and Wellbeing) ;
Boyd, Kathleen A. (University of Glasgow. Institute of Health and Wellbeing) ;
Briggs, Andrew H. (University of Glasgow. Institute of Health and Wellbeing) ;
Iveson, Timothy (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Kerr, Rachel S. (University of Oxford. Department of Oncology) ;
Saunders, Mark P. (The Christie Hospital) ;
Cassidy, Jim (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
Hollander, Niels Henrik (Zealand University Hospital) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Segelov, Eva (Australasian Gastro-Intestinal Trials Group (AGITG) and Monash University and Monash Health) ;
Glimelius, Bengt (University of Uppsala) ;
Harkin, Andrea (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
Allan, Karen (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
McQueen, John (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
Pearson, Sarah (University of Oxford. Department of Oncology, OCTO) ;
Waterston, Ashita (Beatson West of Scotland Cancer Centre (Glasgow, Regne Unit)) ;
Medley, Louise (Royal United Hospital) ;
Wilson, Charles (Addenbrookes Hospital (Cambridge, Regne Unit)) ;
Ellis, Richard (Royal Cornwall Hospitals NHS Trust) ;
Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust) ;
Dhadda, Amandeep S. (Castle Hill Hospital) ;
Hughes, Rob (Mount Vernon Cancer Centre) ;
Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ;
Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ;
Rees, Charlotte (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Olesen, Rene K. (Zealand University Hospital) ;
Propper, David (Barts Cancer Institute (BCI)) ;
Bridgewater, John (University College London) ;
Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust) ;
Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital) ;
Webb, Andrew (Brighton and Sussex University Hospital Trust) ;
Cunningham, David (Royal Marsden (funded by NIHR BRC at the Royal Marsden)) ;
Hickish, Tamas (Poole Hospital/Bournemouth University) ;
Weaver, Andrew (Churchill Hospital, Oxford University Hospitals Foundation Trust) ;
Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ;
Wasan, Harpreet S.. (Hammersmith Hospital (Londres)) ;
Paul, James (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences)
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. [...]
2018 - 10.1038/s41416-018-0319-z
British Journal of Cancer, Vol. 119 (november 2018) , p. 1332-1338
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
